IMGN has its BLA application accepted with priority review for their single arm trial of mirvetuximab soravtansine in platinum resistant ovarian cancer patients whose tumors express high levels of alpha folate receptor .
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.